Globally, the GLP-1 receptor agonist market is valued at USD 62.86 billion in 2025, projected to surge at a 17.5% compound annual growth rate (CAGR) through 2034, driven by expanding indications for obesity, cardiovascular benefits, and even potential neuroprotective effects
Looking ahead, Novo Nordisk has announced a planned list price reduction for Wegovy , which may lower costs over time for both insured and cash-paying individuals
Both experiences are normal
Patients BMI and HbA1c were collected before starting semaglutide and again after 6 and 12 months of using semaglutide
Proper Storage Guidelines for Semaglutide Maintaining the correct temperature is essential for the stability of GLP-1 medications
Both Trulicity and Mounjaro are available only as brand-name drugs with no generic versions currently available